| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
3 companies
Hoyoung Huh is Director at PLRX and has filed Form 4s across 3 companies. Hoyoung Huh's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.5M at current prices.
The biggest single holding is AKTX (~$1.1M) as Director, 10% Owner.
Hoyoung Huh has 23 Form 4 filings on record from May 2015 to August 2026, across 5 companies: Director, 10% Owner at Akari Therapeutics (AKTX), 2025–2026; Director at Pliant Therapeutics (PLRX), 2020–2026; Director at CytomX Therapeutics (CTMX), 2016–2018, and 2 more.
The 32 reported transactions were 20 option or other derivative awards, 7 stock awards, 4 open-market purchases and 1 conversion.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria